i. Unable to take enteral drug (orally or by NG tube) <br/ >ii. Known hypersensitivity to HCQs or other 4-aminoquinoline compounds, or doxycycline <br/ >iii. Already taking HCQs or chloroquine within 1 month due to any reason <br/ >iv. Known G6-PD deficiency <br/ >v. History of retinopathy <br/ >vi. History of congenital cardiac diseases <br/ >vii. QTc > 440 mS at admission, abnormal cardiac rhythm at screening <br/ >viii. Suspected or proven scrub typhus <br/ >ix. Suspected or proven malaria <br/ >x. Patient terminally moribund and unlikely to survive beyond 24 hrs as per physicianâ??s discretion <br/ >xi. Participation in any other clinical trial of an experimental agent treatment for COVID-19 <br/ >xii. Concurrent treatment with other agents with direct acting antiviral activity against COVID-19 <br/ >xiii. Requiring mechanical ventilation at screening <br/ >

i. Unable to take enteral drug (orally or by NG tube) <br/ >ii. Known hypersensitivity to HCQs or other 4-aminoquinoline compounds, or doxycycline <br/ >iii. Already taking HCQs or chloroquine within 1 month due to any reason <br/ >iv. Known G6-PD deficiency <br/ >v. History of retinopathy <br/ >vi. History of congenital cardiac diseases <br/ >vii. QTc > 440 mS at admission, abnormal cardiac rhythm at screening <br/ >viii. Suspected or proven scrub typhus <br/ >ix. Suspected or proven malaria <br/ >x. Patient terminally moribund and unlikely to survive beyond 24 hrs as per physicianâ??s discretion <br/ >xi. Participation in any other clinical trial of an experimental agent treatment for COVID-19 <br/ >xii. Concurrent treatment with other agents with direct acting antiviral activity against COVID-19 <br/ >xiii. Requiring mechanical ventilation at screening <br/ >

N/A

N/A

i. Unable to take enteral drug (orally or by NG tube) <br/ >ii. Known hypersensitivity to HCQs or other 4-aminoquinoline compounds, or doxycycline <br/ >iii. Already taking HCQs or chloroquine within 1 month due to any reason <br/ >iv. Known G6-PD deficiency <br/ >v. History of retinopathy <br/ >vi. History of congenital cardiac diseases <br/ >vii. QTc > 440 mS at admission, abnormal cardiac rhythm at screening <br/ >viii. Suspected or proven scrub typhus <br/ >ix. Suspected or proven malaria <br/ >x. Patient terminally moribund and unlikely to survive beyond 24 hrs as per physicianâ??s discretion <br/ >xi. Participation in any other clinical trial of an experimental agent treatment for COVID-19 <br/ >xii. Concurrent treatment with other agents with direct acting antiviral activity against COVID-19 <br/ >xiii. Requiring mechanical ventilation at screening <br/ >

i. Unable to take enteral drug (orally or by NG tube) <br/ >ii. Known hypersensitivity to HCQs or other 4-aminoquinoline compounds, or doxycycline <br/ >iii. Already taking HCQs or chloroquine within 1 month due to any reason <br/ >iv. Known G6-PD deficiency <br/ >v. History of retinopathy <br/ >vi. History of congenital cardiac diseases <br/ >vii. QTc > 440 mS at admission, abnormal cardiac rhythm at screening <br/ >viii. Suspected or proven scrub typhus <br/ >ix. Suspected or proven malaria <br/ >x. Patient terminally moribund and unlikely to survive beyond 24 hrs as per physicianâ??s discretion <br/ >xi. Participation in any other clinical trial of an experimental agent treatment for COVID-19 <br/ >xii. Concurrent treatment with other agents with direct acting antiviral activity against COVID-19 <br/ >xiii. Requiring mechanical ventilation at screening <br/ >